733
edits
Heart Failure: Difference between revisions
Jump to navigation
Jump to search
→Management of HF beyond medication
| Line 1,005: | Line 1,005: | ||
==Management of HF beyond medication== | ==Management of HF beyond medication== | ||
[[Image:CRT_flowchart.svg|thumb|400px|Figure 8 flowchart CRT]] | |||
[[Image:HF_prognosis_trials.svg|thumb|right|400px|Figure 9 Two-year mortality in landmark contemporary clinical heart failure trials (from Cleland et al)]] | [[Image:HF_prognosis_trials.svg|thumb|right|400px|Figure 9 Two-year mortality in landmark contemporary clinical heart failure trials (from Cleland et al)]] | ||
===Device treatment=== | ===Device treatment=== | ||
Prevention of sudden death is an important goal in HF as approximately half of the deaths occur suddenly and many of these are related to ventricular arrhythmias. Implantable cardioverter-defibrillator (ICD) therapy is recommended in survivors of cardiac arrest , irrespective of EF, when life expectancy is >1 year. (Class I recommendation, level of evidence A). | Prevention of sudden death is an important goal in HF as approximately half of the deaths occur suddenly and many of these are related to ventricular arrhythmias. Implantable cardioverter-defibrillator (ICD) therapy is recommended in survivors of cardiac arrest , irrespective of EF, when life expectancy is >1 year. (Class I recommendation, level of evidence A). | ||